Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 trial

被引：0

作者：

Helsten, Teresa L. ^{[1
]}

Lo, Shelly S. ^{[2
]}

Yau, Christina ^{[3
]}

Kalinsky, Kevin ^{[4
]}

Elias, Anthony D. ^{[5
]}

Wallace, Anne M. ^{[1
]}

Chien, A. Jo ^{[3
]}

Lu, Janice ^{[6
]}

Lang, Julie E. ^{[6
]}

Albain, Kathy S. ^{[2
]}

Stringer-Reasor, Erica ^{[7
]}

Clark, Amy S. ^{[8
]}

Boughey, Judy C. ^{[9
]}

Ellis, Erin D. ^{[10
]}

Yee, Douglas ^{[11
]}

DeMichele, Angela ^{[8
]}

Isaacs, Claudine ^{[12
]}

Perlmutter, Jane ^{[13
]}

Rugo, Hope S. ^{[3
]}

Schwab, Richard ^{[1
]}

Hylton, Nola M. ^{[3
]}

Symmans, W. Fraser ^{[14
]}

Melisko, Michelle E. ^{[15
]}

van't Veer, Laura J. ^{[3
]}

Wilson, Amy ^{[16
]}

Singhrao, Ruby ^{[3
]}

Asare, Smita M. ^{[16
]}

Sanil, Ashish ^{[17
]}

Berry, Donald A. ^{[14
]}

Esserman, Laura J. ^{[3
]}

机构：

[1] Univ Calif San Diego, La Jolla, CA 92093 USA

[2] Loyola Univ, Maywood, IL 60153 USA

[3] Univ Calif San Francisco, San Francisco, CA 94143 USA

[4] Columbia Univ, New York, NY USA

[5] Univ Colorado, Aurora, CO USA

[6] Univ Southern Calif, Los Angeles, CA 90007 USA

[7] Univ Alabama Birmingham, Birmingham, AL USA

[8] Univ Penn, Philadelphia, PA USA

[9] Mayo Clin, Rochester, MN USA

[10] Swedish Canc Inst, Seattle, WA USA

[11] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA

[12] Georgetown Univ, Washington, DC USA

[13] Gemini Grp, Ann Arbor, MI USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[15] Univ Calif San Francisco, La Jolla, CA USA

[16] Quantum Leap Healthcare Collaborat, San Francisco, CA USA

[17] Berry Consultants LLC, Austin, TX USA

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS19-P3-11-02

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3-11-02

引用

页数：4

共 50 条

[1] Efficacy of pertuzumab/trastuzumab /paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Buxton, Meredith
DeMichele, Angela M.
Chia, Stephen
van't Veer, Laura
Chien, Jo
Wallace, Anne
Kaplan, Henry
Lang, Julie
Yee, Douglas
Isaacs, Claudine
Moulder, Stacy
Albain, Kathy
Boughey, Judy
Kemmer, Kathleen
Haley, Barbara
Minton, Susan
Forero, Andres
Nanda, Rita
Elias, Anthony
Korde, Larissa
Viscuzi, Rebecca
Rugo, Hope
Schwab, Richard
Symmans, Fraser
Paoloni, Melissa
Hylton, Nola
Hogarth, Michael
Lyandres, Julia
Perlmutter, Jane
Sanil, Ashish
Yau, Christina
Esserman, Laura
Berry, Don
[J]. CANCER RESEARCH, 2016, 76
[2] Evaluation of Tucatinib plus (Paclitaxel plus Pertuzumab plus Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Potter, David A.
Roesch, Erin
Yau, Christina
Lu, Ruixiao
Wolf, Denise
Samson, Susan
Stafford, Debra
Albain, Kathy S.
Isaacs, Claudine
Trivedi, Meghana
Yee, Douglas
Boughey, Judy
Thomas, Alexandra
Chien, A. Jo
Hylton, Nola
Li, Wen
DeMichele, Angela
Perlmutter, Jane
Symmans, W. Fraser
Hershman, Dawn L.
Melisko, Michelle
Veer, Laura J. van ' t
Wilson, Amy
Asare, Smita M.
Berry, Donald A.
Schwab, Richard
Rugo, Hope S.
Esserman, Laura J.
[J]. CANCER RESEARCH, 2022, 82 (04)
[3] Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Yeung, Kay T.
Kalinsky, Kevin
Yau, Christina
Chien, Amy Jo
Boughey, Judy Caroline
Stringer-Reasor, Erica Michelle
Falkson, Carla Isadora
Albain, Kathy S.
Mayer, Ingrid A.
Trivedi, Meghna S.
Nanda, Rita
Douglas, Emily H.
Omene, Coral Oghenerukevwe
Rugo, Hope S.
Isaacs, Claudine
Parker, Beverly
DeMichele, Angela
Yee, Douglas
Esserman, Laura
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA520 - LBA520
[4] Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
Yeung, Kay T.
Kalinsky, Kevin
Yau, Christina
Chien, Amy Jo
Boughey, Judy Caroline
Stringer-Reasor, Erica Michelle
Falkson, Carla Isadora
Albain, Kathy S.
Mayer, Ingrid A.
Trivedi, Meghna S.
Nanda, Rita
Douglas, Emily H.
Omene, Coral Oghenerukevwe
Rugo, Hope S.
Isaacs, Claudine
Parker, Beverly
DeMichele, Angela
Yee, Douglas
Esserman, Laura
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[5] Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Liu, Minetta C.
Robinson, Patricia A.
Yau, Christina
Wallace, Anne M.
Chien, A. Jo
Stringer-Reasor, Erica
Nanda, Rita
Yee, Douglas
Albain, Kathy S.
Boughey, Judy C.
Han, Heather S.
Elias, Anthony D.
Kalinsky, Kevin
Clark, Amy S.
Kemmer, Kathleen
Isaacs, Claudine
Lang, Julie E.
Lu, Janice
Sanft, Tara
DeMichele, Angela
Hylton, Nola M.
Melisko, Michelle E.
Perlmutter, Jane
Rugo, Hope S.
Schwab, Richard
Symmans, W. Fraser
van't Veer, Laura J.
Haugen, Patricia K.
Wilson, Amy
Singhrao, Ruby
Asare, Smita
Sanil, Ashish
Berry, Donald A.
Esserman, Laura J.
[J]. CANCER RESEARCH, 2020, 80 (04)
[6] Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Pusztai, Lajos
Han, Hyo S.
Yau, Christina
Wolf, Denise
Wallace, Anne M.
Shatsky, Rebecca
Helsten, Teresa
Boughey, Judy C.
Haddad, Tufia
Stringer-Reasor, Erica
Falkson, Carla
Chien, A. Jo
Mukhtar, Rita
Elias, Anthony
Virginia, Borges
Nanda, Rita
Yee, Douglas
Kalinsky, Kevin
Albain, Kathy S.
Muller, Aixa Soyano
Kemmer, Kathleen
Clark, Amy S.
Isaacs, Claudine
Thomas, Alexandra
Hylton, Nola
Symmans, W. Fraser
Perlmutter, Jane
Melisko, Michelle
Rugo, Hope S.
Schwab, Richard
Wilson, Amy
Singhrao, Ruby
Asare, Smita
van't Veer, Laura J.
DeMichele, Angela M.
Sanil, Ashish
Berry, Donald A.
Esserman, Laura J.
[J]. CANCER RESEARCH, 2020, 80 (16)
[7] Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Schwab, Richard
Clark, Amy S.
Yau, Christina
Hylton, Nola
Li, Wen
Wolfe, Denise
Chien, A. Jo
Wallace, Anne M.
Forero-Torres, Andres
Stringer-Reasor, Erica
Nanda, Rita
Jaskowiak, Nora
Boughey, Judy
Haddad, Tufia
Han, Heather S.
Lee, Catherine
Albain, Kathy
Isaacs, Claudine
Elias, Anthony D.
Ellis, Erin D.
Shah, Payal
Lang, Julie E.
Lu, Janice
Tripathy, Debasish
Kemmer, Kathleen
Yee, Douglas
Haley, Barbara
Majure, Melanie
Roesch, Erin
Vaklavas, Christos
Ewing, Cheryl
Helsten, Teresa
Symmans, W. Fraser
Perlmutter, Jane
Rugo, Hope S.
Melisko, Michelle
Wilson, Amy
Singhrao, Ruby
van't Veer, Laura
De Michele, Angela
Asare, Smita
Berry, Don
Esserman, Laura J.
[J]. CANCER RESEARCH, 2019, 79 (13)
[8] Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial
Khattak, Monica N.
Chichura, Anna M.
Lang, Julie E.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (03) : 1423 - 1427
[9] Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
Shatsky, Rebecca Arielle
Thomas, Alexandra
Yau, Christina
Chien, Amy Jo
Falkson, Carla Isadora
Stringer-Reasor, Erica Michelle
Omene, Coral Oghenerukevwe
Trivedi, Meghna S.
Boughey, Judy Caroline
Sanford, Amy
Arora, Mili
Sanft, Tara B.
Nanda, Rita
Isaacs, Claudine
Brown, Thelma
Hylton, Nola
DeMichele, Angela
Yee, Douglas
Esserman, Laura
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA612 - LBA612
[10] Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
Shatsky, Rebecca Arielle
Thomas, Alexandra
Yau, Christina
Chien, Amy Jo
Falkson, Carla Isadora
Stringer-Reasor, Erica Michelle
Omene, Coral Oghenerukevwe
Trivedi, Meghna S.
Boughey, Judy Caroline
Sanford, Amy
Arora, Mili
Sanft, Tara B.
Nanda, Rita
Isaacs, Claudine
Brown, Thelma
Hylton, Nola
DeMichele, Angela
Yee, Douglas
Esserman, Laura
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)

← 1 2 3 4 5 →